LCD Reference Article Response To Comments Article

Response to Comments: DL38664 Implantable Continuous Glucose Monitors (I-CGM)

A58408

Expand All | Collapse All

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	States
First Coast Service Options, Inc.	A and B MAC	09101 - MAC A	J - N	Florida
First Coast Service Options, Inc.	A and B MAC	09102 - MAC B	J - N	Florida
First Coast Service Options, Inc.	A and B MAC	09201 - MAC A	J - N	Puerto Rico Virgin Islands
First Coast Service Options, Inc.	A and B MAC	09202 - MAC B	J - N	Puerto Rico
First Coast Service Options, Inc.	A and B MAC	09302 - MAC B	J - N	Virgin Islands

Article Information

General Information

Article ID
A58408

Article Title
Response to Comments: DL38664 Implantable Continuous Glucose Monitors (I-CGM)

Article Type
Response to Comments

Original Effective Date
10/11/2020

Retirement Date
N/A

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Article Guidance

Article Text

The following are the comment summaries and contractor responses for First Coast Service Options Proposed Local Coverage Determination (LCD) DL38664 Implantable Continuous Glucose Monitors (I-CGM) which was posted for comment on April 30, 2020, and presented at the May 13, 2020 Open Meeting. All comments were reviewed and incorporated into the final LCD where applicable.

Response To Comments

Number	Comment	Response
1	Multiple comments were received asking that the blood glucose monitoring (BGM) requirement for frequent testing be removed for various reasons. These reasons included “the requirement seems unfair and not realistic”, “Durable medical equipment (DME) providers are reluctant or refuse to provide 4 or more test strips per day”, “there is insufficient data to support a specific number of self-monitoring of blood glucose tests that should be performed to predict the effectiveness of CGM”, “patients who currently use older style CGMs may not be testing as frequently given these devices are now labelled to replace finger sticks”, and “data suggests such frequent monitoring is not required and would be considered excessive”.	We thank you for your comments, after further consideration and review, this criteria is completely removed from the policy.
2	Multiple comments were received asking that we clarify that some beneficiaries may choose to transition to an implantable CGM from another CGM technology and would therefore, not have been performing finger stick testing using a blood glucose monitor.	We appreciate your comments, after further consideration and review, the policy is revised to include an exception statement in the limitations section of the LCD for those beneficiaries who have previously met the coverage criteria for a non-implantable continuous glucose monitor and subsequently choose to switch to an implantable device.
3	An international firm that stated, “We represent a number of clients who develop, manufacture, and market technologies for use by patients with diabetes, as well as other healthcare stakeholders” provided this comment. The client list of those whom this firm represents was not provided. The Medicare program should not make duplicative payment for glucose monitoring supplies. If an I-CGM is used to monitor a patient’s glucose, the billing entity should also be responsible for supplying any blood glucose monitor (“BGM”) supplies necessary for I-CGM use. A closer review of the evidence for I-CGM should be conducted to determine whether this device and related service are reasonable and necessary for Medicare beneficiaries. The Draft LCD does not discuss any published evidence demonstrating improved clinical outcomes conferred on Medicare beneficiaries by I-CGMs. In establishing coverage and payment for I-CGMs and associated supplies, First Coast should ensure that the Medicare program does not double-pay for glucose monitoring supplies. As noted in the Draft LCD, I-CGM, like therapeutic CGMs, “are designed to replace finger stick blood glucose testing”. Consistent with this intended use, the Glucose Monitors LCD (L33822) confirms that claims for standard BGM and related supplies will be denied if the patient is already receiving a therapeutic CGM for glucose monitoring. The Draft LCD does not recognize that I-CGMs are intended to substitute for standard BGM (and their associated supplies). The Draft LCD should be revised to make clear that Medicare will not provide separate payment for BGM supplies in connection with beneficiaries who receive I-CGM. Instead, the billing entity that receives payment for I-CGMs should be responsible for supplying the patient with the required BGM supplies needed to operate the device (such as test strips, lancets, lancing device, and calibration solutions). This approach would mirror the approach for the supply allowance for therapeutic CGMs (K0553). Otherwise, the Medicare program would be double-paying for glucose monitoring supplies that are neither reasonable nor necessary for beneficiaries who receive an I-CGM. The commenter indicates they noted that there does not appear to be a discussion of published evidence supporting the reasonable and necessary use for I-CGMs in the Medicare population. Medicare policies require that a service must, among other things, be furnished in accordance with accepted standards of medical practice, meet but not exceed the patient’s medical need, and is at least as beneficial as an existing and available medically appropriate alternative. The commenter indicates the Draft LCD does not discuss evidence that demonstrates I-CGMs improve clinical outcomes for Medicare beneficiaries, such as through reductions in HbA1C, hypoglycemic events, or other endpoints that show the device results in a clinical benefit for patients. The Draft LCD also noted that these pivotal trials featured “few patients…in the Medicare aged population”, further calling into question the current evidence as fulfilling Medicare coverage requirements. With respect to whether I-CGM is consistent with accepted standards of medical practice, the professional society recommendations and consensus statements cited in the Draft LCD are not actually based on an assessment of I-CGMs. Rather, these recommendations and statements were made following consideration of the evidence supporting CGMs that use an external sensor and monitor, devices that do have published data demonstrating their impact on clinical outcomes. Rather than requiring I-CGMs to demonstrate their own ability to improve outcomes, it seems that all of the evidence cited in favor of the clinical benefits was derived from studies of external sensor CGMs. This evidence relates to an entirely different product category covered under a separate Medicare benefit. As a result, the commenter strongly urges First Coast to reassess the evidence in support of I-CGMs to determine if this separate and independent device and service meet the appropriate standard for Medicare coverage.	Thank you for your comments. Evidence exists that demonstrates the use of implantable glucose monitors in the Medicare population. The objective data is similar to external continuous glucose monitors (“CGMs”) and the current data indicates that this device has clinical efficacy regardless of age. In addition, this device is categorized by the Food and Drug Administration (FDA) as a therapeutic CGM. At present, the use of external CGMs is a covered DME benefit for non-Medicare as well as Medicare patients. While few, there are patients in the Medicare aged population in the studies; demonstrating strong indication that the data is generalized to patients in the Medicare population. In regards to your recommendation indicating the Draft LCD should be revised to make clear that Medicare will not provide separate payment for BGM supplies in connection with beneficiaries who receive I-CGM, this issue is outside the scope of this LCD.
4	The commenter has concern with criterion #6 where the LCD states, “…every six months following initial prescription of I-CGM, the treating practitioner has an in-person visit…” Given implantable CGM requires a health care professional (HCP) to insert the device, isn’t this criterion already met? According to the commenter this is redundant and not necessarily a requirement that makes sense in the context of an implantable device. The commenter has a concern about criterion #2 where a patient must be performing four times a day testing to become eligible for an implantable CGM. After the adoption of CGM, few of these patients use a blood glucose meter four times per day. If this language is part of the criteria, this may preclude patients to transition over to implantable CGM if it is medically necessary.	We thank you for your comment and for bringing to our attention that this may be an unnecessary burden for the patient and provider. The requirement was intended to encourage routine follow-up patient care. This requirement is removed from the policy and replaced with “recommended follow-up care is expected”. In regards to criterion # 2, after further consideration and review, the decision was made to remove this requirement from the LCD.
5	A commenter has requested that the coverage for Eversense CGM in the Medicare population be fast-tracked, especially at this time of uncertainty in our country’s ability to provide medical care to individuals with diabetes. There have been patients that have had issues obtaining supplies for the other CGM devices either due to inability to go to the pharmacy to get supplies or distribution issues with stores closing or distribution centers understaffed. The commenter would also like to disagree with the coverage criteria requiring a patient test four times a day as setting a number on the test required per day to make the patient eligible for any CGM device counters the ADA recommendations for treating people with diabetes. To the commenter’s knowledge, there is no data source that supports the predictive capability with CGM based on historical use of a Blood Glucose Meter.	We thank you for your comment. In regards to fast tracking the CGM coverage for the Medicare population, the development of a new local coverage determinations (LCD) and associated local coverage articles (LCA) must follow the process and guidelines that have been outlined in the CMS Internet-Only Manuals (IOMs) Publication 100-08 Medical Program Integrity Manual, Chapter 13 Local Coverage Determinations. Also, in regards to the coverage criterion of testing four times a day, after further consideration and review, the decision was made to remove this requirement from the LCD.
6	One comment was received recommending modification of the wording relating to insulin treatment to eliminate the word “injections” as there is inhaled insulin used by some patients. To accommodate that reality, the wording should reflect “multiple daily administrations” with insulin, not “injections”. The commenter further requests the consideration to permanently adopt the temporary waiver CMS issued under the COVID-19 Public Health Emergency that permits face-to-face office visit requirements for Medicare coverage of certain services to be performed by telehealth. Utilizing telehealth for the required biannual office visit to maintain CGM coverage will continue to be an important new safety protocol for people with diabetes and providers will reduce the administrative and resource burdens associated with a face-to-face in-office visit that can be just as effectively performed by telehealth.	Thank you for your comment, after further consideration and review, the statement related to insulin treatment and the elimination of the word “injections”, is revised and the statement “injections of insulin” is replaced with multiple daily “administrations of insulin” taking into account the other forms of insulin. Regarding the permanent adoption of the temporary waiver under COVID-19, a waiver of this type of requirement is beyond the scope of this LCD.
7	A commenter requests that “CPT III code 0447T will be included in the accompanying LCD Article to ensure providers understand that this code may be used for individuals who may need removal of the sensor only. We support the discussion around adding 0447T to the paragraph, but do not tie in specific diagnosis codes to the use of that code as there may be other circumstances that require removal irrespective of diagnosis”.	Thank you for your comment. CPT III code 0447T has been added to the billing and coding article indicating that diagnosis code limitations will not be applied at this time.

Coding Information

CPT/HCPCS Codes

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-CM Codes that Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-PCS Codes

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

Additional ICD-10 Information

Bill Type Codes

Code	Description

Revenue Codes

Code	Description

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion
			N/A	N/A

Non-Excluded CPT/HCPCS Ended Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion

Revision History Information

N/A

Associated Documents

Updated On	Effective Dates	Status
08/21/2020	10/11/2020 - N/A	Currently in Effect	You are here

Keywords

N/A

Read the Article Disclaimer

License Agreements
American Medical Association Current Procedural Terminology
American Dental Association Current Dental Terminology
American Hospital Association NUBC UB-04

Please review the licensing information below and indicate your agreement and acceptance.

License for Use of Current Procedural Terminology (CPT)

End User Point and Click Agreement: CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the American Medical Association (AMA).

You, your employees, and agents are authorized to use CPT only as agreed upon with the AMA internally within your organization within the United States for the sole use by yourself, employees, and agents. Use is limited to use in Medicare, Medicaid or other programs administered by the Centers for Medicare and Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized herein must be obtained through the AMA, CPT Intellectual Property Services, AMA Plaza, 330 Wabash Ave., Suite 39300, Chicago, IL 60611-5885. Applications are available at the AMA Web site, http://www.ama-assn.org/go/cpt http://www.ama-assn.org/go/cpt.

Applicable FARS\DFARS Restrictions Apply to Government Use.

This product includes CPT which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, AMA Plaza, 330 N. Wabash Ave., Suite 39300, Chicago, IL 60611-5885. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of FAR 52.227-14 (December 2007) and/or subject to the restricted rights provisions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT should be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CPT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material contained on this page. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

License For Use of Current Dental Terminology (CDT^TM)

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. By clicking below on the button labeled "I accept", you hereby acknowledge that you have read, understood, and agreed to all terms and conditions set forth in this agreement.

If you do not agree with all terms and conditions set forth herein, click below on the button labeled "I do not accept" and exit from this computer screen.

If you are acting on behalf of an organization, you represent that you are authorized to act on behalf of such organization and that your acceptance of the terms of this agreement creates a legally enforceable obligation of the organization. As used herein, "you" and "your" refer to you and any organization on behalf of which you are acting.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association web site, http://www.ADA.org/ http://www.ADA.org/.

Applicable Federal Acquisition Regulation Clauses (FARS)/Department of Defense Federal Acquisition Regulation supplement (DFARS) Restrictions Apply to Government Use.

Organizations who contract with CMS acknowledge that they may have a commercial CDT license with the ADA, and that use of CDT codes as permitted herein for the administration of CMS programs does not extend to any other programs or services the organization may administer and royalties dues for the use of the CDT codes are governed by their commercial license.

ADA DISCLAIMER OF WARRANTIES AND LIABILITIES

CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values, or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for software, including any CDT and other content contained therein, is with (insert name of applicable entity) or the CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The ADA is a third-party beneficiary to this Agreement.

CMS DISCLAIMER

The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CDT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material covered by this license. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use software. Instead, you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

License For Use of National Uniform Billing Committee (NUBC) UB-04

These materials contain NUBC Official UB-04 Specifications (UB-04 Data), which is copyrighted by the American Hospital Association (AHA).

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN. IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use UB-04 Data only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of UB-04 Data is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this Agreement. You acknowledge that the AHA holds all copyright, trademark, and other rights in UB-04 Data. You shall not remove, alter, or obscure any AHA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including, by way of illustration and not by way of limitation, making copies of UB-04 Data for resale and/or license, transferring copies of UB-04 Data to any party not bound by this agreement, creating any modified or derivative work of UB-04 Data, or making any commercial use of UB-04 Data. License to use UB-04 Data for any use not authorized herein must be obtained through the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois, 60606. Applications are available at the NUBC website, http://www.nubc.org/ http://www.nubc.org/.
The UB-04 Data included in this product is commercial technical data and/or computer databases and/or commercial computer software and/or commercial computer software documentation, as applicable, which was developed exclusively at private expense by the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois 60606. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.
AHA DISCLAIMER OF WARRANTIES AND LIABILITIES. UB-04 Data is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The sole responsibility for the software, including any UB-04 Data and other content contained therein, is with the Medicare/Medicaid Contractor or the CMS; and no endorsement by the AHA is intended or implied. The AHA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The AHA is a third-party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the AHA, the copyright holder. Any questions pertaining to the license or use of the UB-04 Data should be addressed to the AHA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE UB-04 DATA. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Submit Feedback/Ask a Question

Response to Comments: DL38664 Implantable Continuous Glucose Monitors (I-CGM)

Document Note

Note History

Contractor Information

Article Information

General Information

CMS National Coverage Policy

Article Guidance

Response To Comments

Coding Information

Bill Type Codes

Revenue Codes

CPT/HCPCS Codes

Group 1

CPT/HCPCS Modifiers

Group 1

ICD-10-CM Codes that Support Medical Necessity

Group 1

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

ICD-10-PCS Codes

Group 1

Additional ICD-10 Information

Bill Type Codes

Revenue Codes

Other Coding Information

Group 1

Coding Table Information

Revision History Information

Associated Documents

Keywords

Page Help for Article - Response to Comments: DL38664 Implantable Continuous Glucose Monitors (I-CGM) (A58408)

Introduction

Finding a specific code

More information

Printing a Document to PDF

Get email updates

CMS & HHS WEBSITES

HELPFUL LINKS

RSS FEEDS